137 related articles for article (PubMed ID: 38644522)
41. Hidradenitis suppurativa (HS) is associated with low socioeconomic status (SES): A cross-sectional reference study.
Deckers IE; Janse IC; van der Zee HH; Nijsten T; Boer J; Horváth B; Prens EP
J Am Acad Dermatol; 2016 Oct; 75(4):755-759.e1. PubMed ID: 27453539
[TBL] [Abstract][Full Text] [Related]
42. Alexithymia affects patients with hidradenitis suppurativa.
Chiricozzi A; Giovanardi G; Caro DRC; Iannone M; Garcovich S; Dini V; De Simone C; Franceschini C; Oranges T; Mingrone G; Capristo E; Di Raimondo C; Bianchi L; Peris K
Eur J Dermatol; 2018 Aug; 28(4):482-487. PubMed ID: 30325328
[TBL] [Abstract][Full Text] [Related]
43. Characterization of comorbid conditions burdening hidradenitis suppurativa: a multicentric observational study.
Chiricozzi A; Giovanardi G; Caposiena Caro DR; Iannone M; De Simone C; Cannizzaro MV; Oranges T; Fossati B; Di Matteo E; Dini V; Bianchi L; Peris K
G Ital Dermatol Venereol; 2020 Jun; 155(3):335-340. PubMed ID: 30295448
[TBL] [Abstract][Full Text] [Related]
44. Assessment of Overall and Specific Cancer Risks in Patients With Hidradenitis Suppurativa.
Jung JM; Lee KH; Kim YJ; Chang SE; Lee MW; Choi JH; Won CH; Lee WJ
JAMA Dermatol; 2020 Aug; 156(8):844-853. PubMed ID: 32459291
[TBL] [Abstract][Full Text] [Related]
45. Baseline Characteristics of a National French E-Cohort of Hidradenitis Suppurativa in ComPaRe and Comparison with Other Large Hidradenitis Suppurativa Cohorts.
Condamina M; Penso L; Tran VT; Hotz C; Guillem P; Villani AP; Perrot P; Bru MF; Jacquet E; Nassif A; Bachelez H; Wolkenstein P; Beylot-Barry M; Richard MA; Ravaud P; Viguier M; Sbidian E
Dermatology; 2021; 237(5):748-758. PubMed ID: 33503635
[TBL] [Abstract][Full Text] [Related]
46. Systemic associations of hidradenitis suppurativa.
Kohorst JJ; Kimball AB; Davis MD
J Am Acad Dermatol; 2015 Nov; 73(5 Suppl 1):S27-35. PubMed ID: 26470611
[TBL] [Abstract][Full Text] [Related]
47. Prevalence of type 2 diabetes mellitus among patients with hidradenitis suppurativa in the United States.
Garg A; Birabaharan M; Strunk A
J Am Acad Dermatol; 2018 Jul; 79(1):71-76. PubMed ID: 29339240
[TBL] [Abstract][Full Text] [Related]
48. Epidemiology of hidradenitis suppurativa.
Bukvić Mokos Z; Markota Čagalj A; Marinović B
Clin Dermatol; 2023; 41(5):564-575. PubMed ID: 37696341
[TBL] [Abstract][Full Text] [Related]
49. Hidradenitis suppurativa and rheumatoid arthritis: evaluating the bidirectional association.
Kridin K; Shavit E; Damiani G; Cohen AD
Immunol Res; 2021 Dec; 69(6):533-540. PubMed ID: 34409549
[TBL] [Abstract][Full Text] [Related]
50. Physical and psychosocial comorbidities of pediatric hidradenitis suppurativa: A retrospective analysis.
Seivright JR; Collier E; Grogan T; Hogeling M; Shi VY; Hsiao JL
Pediatr Dermatol; 2021 Sep; 38(5):1132-1136. PubMed ID: 34463372
[TBL] [Abstract][Full Text] [Related]
51. Burden, predictors and temporal relationships of comorbidities in patients with hidradenitis suppurativa: a hospital-based cohort study.
Jørgensen AR; Yao Y; Ghazanfar MN; Ring HC; Thomsen SF
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):565-573. PubMed ID: 31442338
[TBL] [Abstract][Full Text] [Related]
52. Hidradenitis Suppurativa and Concurrent Psoriasis: Comparison of Epidemiology, Comorbidity Profiles, and Risk Factors.
Pinter A; Kokolakis G; Rech J; Biermann MHC; Häberle BM; Multmeier J; Reinhardt M
Dermatol Ther (Heidelb); 2020 Aug; 10(4):721-734. PubMed ID: 32500484
[TBL] [Abstract][Full Text] [Related]
53. Hidradenitis Suppurativa and Bipolar Disorders: A Population-Based Study.
Tzur Bitan D; Berzin D; Cohen A
Dermatology; 2020; 236(4):298-304. PubMed ID: 31910425
[TBL] [Abstract][Full Text] [Related]
54. Hidradenitis suppurativa and schizophrenia: a nationwide cohort study.
Tzur Bitan D; Berzin D; Cohen AD
J Eur Acad Dermatol Venereol; 2020 Mar; 34(3):574-579. PubMed ID: 31587377
[TBL] [Abstract][Full Text] [Related]
55. Metformin Treatment of Hidradenitis Suppurativa: Effect on Metabolic Parameters, Inflammation, Cardiovascular Risk Biomarkers, and Immune Mediators.
Hambly R; Kearney N; Hughes R; Fletcher JM; Kirby B
Int J Mol Sci; 2023 Apr; 24(8):. PubMed ID: 37108132
[TBL] [Abstract][Full Text] [Related]
56. Evaluation of Cardiovascular Risk in Hidradenitis Suppurativa Patients Using Heart Rate Variability (HRV) Analysis.
Skroza N; Mambrin A; Proietti I; Balduzzi V; Bernardini N; Marchesiello A; Michelini S; Tolino E; Volpe S; Maddalena P; Ciaramella A; Raimondi G; Potenza C
Cardiovasc Ther; 2020; 2020():1321782. PubMed ID: 32695226
[TBL] [Abstract][Full Text] [Related]
57. Analysis of Characteristics and Trends in Treatment Response of Hidradenitis Suppurativa Patients: A Southern US Cohort Study.
Peterson GC; Preston A; Frieder J; Wang X; Paek SY
Dermatology; 2020; 236(5):413-420. PubMed ID: 31935718
[TBL] [Abstract][Full Text] [Related]
58. Association of Birth Weight, Childhood Body Mass Index, and Height With Risk of Hidradenitis Suppurativa.
Jørgensen AR; Aarestrup J; Baker JL; Thomsen SF
JAMA Dermatol; 2020 Jul; 156(7):746-753. PubMed ID: 32347905
[TBL] [Abstract][Full Text] [Related]
59. Adverse pregnancy and maternal outcomes in women with hidradenitis suppurativa.
Fitzpatrick L; Hsiao J; Tannenbaum R; Strunk A; Garg A
J Am Acad Dermatol; 2022 Jan; 86(1):46-54. PubMed ID: 34126093
[TBL] [Abstract][Full Text] [Related]
60. Decreased number of circulating endothelial progenitor cells in hidradenitis suppurativa patients.
Matusiak Ł; Batycka-Baran A; Bieniek A; Szepietowski JC
Dermatology; 2015; 230(3):228-33. PubMed ID: 25721353
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
